Data investigation
When the Appetite Center Is Damaged
For people whose obesity follows damage to the brain's appetite center, almost nothing works. A study of 116 patients found modest average weight loss and something more important: 8% hospitalized for hormonal decompensation.
For people whose obesity comes from damage to the brain’s appetite center, usually after surgery or radiotherapy for a tumor near the pituitary, most treatments do little. The exception so far is setmelanotide, a daily injection whose label has covered this condition since March 2026.[2] For GLP-1 drugs, a study of 116 such patients found modest average weight loss and something more important: 8% were hospitalized for hormonal decompensation.[1]
Why this population is different
Craniopharyngioma is a benign tumor that grows near the pituitary gland and hypothalamus. Removing or irradiating it frequently damages the hypothalamus, the structure that regulates hunger, fullness, temperature and the hormonal axes beneath it. The result, acquired hypothalamic obesity, is relentless weight gain driven by a broken regulator rather than by behavior. It is a different mechanism from the cortisol excess behind obesity in Cushing’s syndrome.
Most of these patients also depend on replacement hormones taken by mouth: hydrocortisone for adrenal function, desmopressin for water balance, often thyroid hormone and others. That dependence is what makes the safety finding below specific to them.
The safety finding
| Event | Proportion |
|---|---|
| Adrenal insufficiency decompensation | 12% |
| Vasopressin deficiency decompensation | 10% |
| Required hospitalization | 8% |
| Gastrointestinal intolerance leading to stopping | 13% |
This is why a general statement that these drugs are well tolerated does not settle anything for a particular patient. The commonest side effect of the class is gut upset, mild and self-limiting in most people. In this population, that same side effect is how the drug becomes dangerous.
The authors’ conclusion follows directly: specific endocrine monitoring is essential. That is a concrete requirement, not a hedge.
The average is the wrong number
Over a mean follow-up of 44 months, average weight loss was −4.6%, with a standard deviation of 12.5.
The spread is nearly three times the average.
A distribution like that stretches from very large losses to substantial gains. The supporting figures confirm it: 51% of patients lost at least 5% of their weight and 28% lost at least 10%. Against a mean of only 4.6%, that means the remaining half did badly enough to pull the average down that far.
So “these drugs produce about 5% weight loss in hypothalamic obesity” is the wrong summary. Roughly half of patients responded usefully, a quarter responded well, and the rest did not respond or gained. Nobody can currently tell in advance which group someone will land in.
| Comparison | Result |
|---|---|
| Semaglutide (mean dose 1.2 mg/week) | −6.8%, the largest of the drugs used |
| Semaglutide, patients without diabetes | −8.5% (± 12.3) vs −3.9% (± 10.0) with diabetes, p = 0.032 |
That diabetes gap matches the pattern seen throughout this drug class, where type 2 diabetes reliably reduces weight response. Note the dose too: a mean of 1.2 mg per week is well below the 2.4 mg used for weight management, so this is a submaximal-dosing result.
What it does and does not establish
- It is retrospective. Records from 16 centers, not a trial, with no control group.
- It does not transfer to common obesity, and common obesity results do not transfer here. The regulator itself is damaged, which is a different disease.
- The dosing was submaximal, so response at full dose is unknown, and so is whether the endocrine risk would rise with it.
- Modest average benefit is still benefit in a condition with very few options, and half of patients reaching 5% is not nothing.
For anyone in this situation, the practical takeaway is the monitoring rather than the percentage: sick-day rules for steroid replacement, a plan for what to do when vomiting starts, and endocrine follow-up arranged before the first dose rather than after the first crisis.
The drug approved for this condition
Setmelanotide (Imcivree) is not a GLP-1. It is a melanocortin-4 receptor agonist, and FDA extended its label in March 2026 to people aged 4 and older with acquired hypothalamic obesity.[2] In the phase 3 TRANSCEND trial, 120 people aged 4 to 66 were assigned 2:1 to setmelanotide or placebo. At 52 weeks BMI had changed by −16.5% on the drug and +3.3% on placebo, and hunger scores fell further too.[3]
It has costs of its own. Serious adverse events were reported in 28% on setmelanotide against 8% on placebo, and skin darkening, nausea, vomiting and headache were the most common events. The manufacturer funded the trial. It also was not a comparison with GLP-1 drugs: it was randomized and the French study above was not, so the two sets of numbers cannot be set side by side.[3] Nausea and vomiting matter here for the same reason as above, so the endocrine plan is worth settling before the first dose of this drug too.
Frequently Asked Questions
References
- 1.Lambert F, Guillon E, Gatta-Cherifi B, et al. Effectiveness and safety of GLP-1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real-world study Diabetes, Obesity and Metabolism. 2026. PMID: 41153084.
- 2.Rhythm Pharmaceuticals IMCIVREE (setmelanotide) injection: prescribing information (section 1) DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9
- 3.Miller JL, van Santen HM, Phillips SA, et al. Setmelanotide for the Treatment of Acquired Hypothalamic Obesity New England Journal of Medicine. 2026. PMID: 42418774.
Compare the sellers
Related research
A Weight Drug for Having Too Little Fat
Lipodystrophy is the opposite of obesity: people are missing fat tissue, and are severely metabolically ill because of it. In a cohort given tirzepatide, those with familial partial lipodystrophy cut their daily insulin by a median of 109 units.
6 min read
Drinking on a GLP-1: What the Label Actually Says
The Wegovy label contains no guidance about drinking at all; we checked every one of its eleven uses of the word. What it does warn about, and what two randomized trials found when they tested the pairing deliberately.
8 min read
What Instagram Leaves Out
Researchers compared semaglutide posts across five platforms against what the STEP trials recorded. The most useful finding is an omission: the drug's most common side effects were absent from Instagram.
6 min read
The First Pill-Versus-Pill Trial
Orforglipron beat oral semaglutide on HbA1c at every dose pairing in 1,698 adults, and produced twice the dropouts and three times the heart rate rise. Both halves are the result.
8 min read
The Top Dose Keeps Not Being Worth It
Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.
7 min read
What Tripling the Dose Buys
A higher semaglutide dose produced 18.7% weight loss against 15.6% on the standard dose. Three extra percentage points is the benefit; the costs are in the safety table.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
YourEra
Semaglutide at $99/month, well below the typical price
From $99/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →Sesame Care
Oral orforglipron alongside the injectables
From $149/mo + care fee
Get started →